Paola Sindaco

Paola Sindaco

Auto-generated profile, based on publicly available information

Paola Sindaco

Genetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PSPaola Sindaco
Paola Sindaco
HPHritisha Pandey
Hritisha Pandey
CIColleen Isabelle
Colleen Isabelle
NCNitin Chakravarti
Nitin Chakravarti
JBJonathan Brammer
Jonathan Brammer
AMAnjali Mishra
Anjali Mishra
Cytokines are a vital component of the immune system that controls the activation and growth of blood cells. However, chronic overexpression of cytokines can trigger cellular events leading to malignant transformation. The cytokine interleukin-15 (IL-15) is of particular interest, which has been shown to contribute to the development and progression of various hematological malignancies. This review will provide an overview of the impact of the immunopathogenic function of IL-15 by studying its role in cell survival, proliferation, inflammation, and treatment resistance. We will also review therapeutic approaches for inhibiting IL-15 in blood cancers.

9 October 2018 in Acta Haematologica
Verified
Journal Article
Open access
PDF file
Francesco GaudioFrancesco Gaudio
Francesco Gaudio
PPPasquale Pedote
Pasquale Pedote
AAArtor Niccoli Asabella
Artor Niccoli Asabella
Giuseppe IngravalloGiuseppe Ingravallo
Giuseppe Ingravallo
PSPaola Sindaco
Paola Sindaco
GSGiorgina Specchia
Giorgina Specchia
Hodgkin’s lymphoma (HL) is now a highly curable disease, with an improving 5-year survival rate that has now reached 86%. At the time of presentation, HL is usually almost entirely confined to the lymph nodes. We performed a retrospective single-institution study of 384 cases with a median follow-up of 44 months, with the aim of identifying clinical and radiological characteristics and outcomes of patients with bone HL; 32 patients (8%) had primary bone involvement, always with concurrent nodal disease. These included 22 men (69%) and 10 women (31%) with the median age as 41 years. Advanced stages and nodular sclerosis histology prevailed among the subgroup. Radiographic features of bone HL are not specific but indicate a destructive malignant process with osteosclerosis and/or osteolysis. With current chemotherapeutic regimens, the long-term prognosis of patients with osseous HL appears good. The presence of bone lesions in HL should not be interpreted as implying a worse prognosis than without bone involvement.

15 March 2019 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
SCStefano Casola
Stefano Casola
LPLaura Perucho
Laura Perucho
CTClaudio Tripodo
Claudio Tripodo
PSPaola Sindaco
Paola Sindaco
MPMaurilio Ponzoni
Maurilio Ponzoni
FFFabio Facchetti
Fabio Facchetti

1 January 2005 in BioFactors
Verified
Journal Article
Closed access
PDF file
MMaria Cristina Polidori
Maria Cristina Polidori
Domenico PraticòDomenico Praticò
Domenico Praticò
TITiziana Ingegni
Tiziana Ingegni
EMElena Mariani
Elena Mariani
LSLiana Spazzafumo
Liana Spazzafumo
AGAvasas Study Group
Avasas Study Group

10 October 2024 in Blood
Verified
Journal Article
Closed access
JJJana von Jan
Jana von Jan
STSanna Timonen
Sanna Timonen
TBTill Braun
Till Braun
QJQU JIANG
QU JIANG
AIAleksandr Ianevski
Aleksandr Ianevski
MHMarco Herling
Marco Herling
T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated with marked chemotherapy resistance and continued poor clinical outcomes. Current treatments, that is, the CD52-antibody alemtuzumab, offer transient responses, with relapses being almost inevitable without consolidating allogeneic transplantation. Recent more detailed concepts of T-PLL’s pathobiology fostered the identification of actionable vulnerabilities: (1) altered epigenetics, (2) defective DNA damage responses, (3) aberrant cell-cycle regulation, and (4) deregulated prosurvival pathways, including T-cell receptor and JAK/STAT signaling. To further develop related preclinical therapeutic concepts, we studied inhibitors of histone deacetylases ([H]DACs), B-cell lymphoma 2 (BCL2), cyclin-dependent kinase (CDK), mouse double minute 2 (MDM2), and classical cytostatics, using (1) single-agent and combinatorial compound testing in 20 well-characterized and molecularly profiled primary T-PLL (validated by additional 42 cases) and (2) 2 independent murine models (syngeneic transplants and patient-derived xenografts). Overall, the most efficient/selective single agents and combinations (in vitro and in mice) included cladribine, romidepsin ([H]DAC), venetoclax (BCL2), and/or idasanutlin (MDM2). Cladribine sensitivity correlated with expression of its target RRM2. T-PLL cells revealed low overall apoptotic priming with heterogeneous dependencies on BCL2 proteins. In additional 38 T-cell leukemia/lymphoma lines, TP53 mutations were associated with resistance toward MDM2 inhibitors. P53 of T-PLL cells, predominantly in wild-type configuration, was amenable to MDM2 inhibition, which increased its MDM2-unbound fraction. This facilitated P53 activation and downstream signals (including enhanced accessibility of target-gene chromatin regions), in particular synergy with insults by cladribine. Our data emphasize the therapeutic potential of pharmacologic strategies to reinstate P53-mediated apoptotic responses. The identified efficacies and their synergies provide an informative background on compound and patient selection for trial designs in T-PLL.

22 May 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
GVGabriele Varano
Gabriele Varano
SLSilvia Lonardi
Silvia Lonardi
PSPaola Sindaco
Paola Sindaco
IPIlaria Pietrini
Ilaria Pietrini
GMGaia Morello
Gaia Morello
SCStefano Casola
Stefano Casola
The B-cell receptor (BCR) is critical for mature B-cell lymphomas (BCL), serving as a therapeutic target. We show that high-grade BCLs with MYC and BCL2 rearrangements [HGBCL–double-hit (DH)–BCL2] predominantly exhibit immunoglobulin heavy (IGH) chain silencing, leading to BCR shutdown. IGH-silenced HGBCL-DH-BCL2 (IGHUND) tumors differ from IGH+ counterparts in germinal center (GC) zone programs, MYC expression, and immune infiltrate. Whereas IGH+ HGBCL-DH-BCL2 tumors favor IGM/IG-κ expression, IGHUND counterparts complete IGH isotype switching and IG-λ rearrangements. IGHUND lymphomas retain productive IGHV rearrangements and require IGH for optimal fitness. BCR silencing, caused by accelerated IGH turnover and reduced IGH expression, precedes HGBCL-DH-BCL2 onset, inducing RAG1/2-dependent IG light chain editing and facilitating t(8;22)/IGL::MYC translocations. IGHUND HGBCL-DH-BCL2 models exhibit reduced sensitivity to the CD79B-targeting antibody–drug conjugate polatuzumab vedotin. Collectively, HGBCL-DH-BCL2 commonly arises from isotype-switched t(14;18)+ GC B cells, which edit IG light chains, fueling intraclonal diversification, BCR extinction, and t(8;22) while maintaining IGH dependence, with clinical implications. Significance: These findings link BCR silencing in IGH isotype-switched t(14;18)+ GC B cells to RAG1/2 expression, which triggers IG light chain editing and predisposes to IGL::MYC translocations, promoting HGBCL. In HGBCL with MYC and BCL2 rearrangements, BCR silencing protects from polatuzumab vedotin killing. See related commentary by Shevchenko and Hodson, p. 284